← All indications
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.
Subtype terms (4)
More specific conditions that are subtypes of Bone Neoplasms in the MeSH hierarchy.
- Adamantinoma
2 drugs (1 approved, 1 experimental)
- Femoral Neoplasms
- Skull Neoplasms
- Spinal Neoplasms
3 drugs approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 2 trials (20)
Phase 1 trials (10)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (25)
- Daiichi Sankyo
- Gradalis, Inc.
- Qilu Pharmaceutical Co., Ltd.
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Cancer Institute (NCI)
- Winnipeg Regional Health Authority
- University of Manitoba
- Hebei University
- Cairo University
- Canadian Cancer Trials Group
- Centre Henri Becquerel
- Emory University
- McMaster University
- University of Toronto
- Utrecht University
- University of Alberta
- Fudan University
- St. Louis University
- University of Barcelona
- University of Texas, San Antonio
- Canadian Cancer Society
- Canadian Institutes of Health Research (CIHR)
- The Physicians' Services Incorporated Foundation
- Sanchez Cancer Center
- St. Jude Children's Hospital
Organization Involved with Phase 2 Indications (26)
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- Ipsen
- Bayer
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Cancer Trials Ireland
- Centre Hospitalier de la Région d'Annecy
- Hoosier Cancer Research Network
- Sarcoma Alliance for Research through Collaboration
- Stanford University
- The Adelaide and Meath Hospital
- University of Michigan
- Wake Forest University
- Yonsei University
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
- Leiden University
- Technion University
- University of Texas at Houston
- CH Annecy
- University of Nantes
- Developmental Therapeutics Consortium
- Iovance
- French Lung Cancer Group
- Actuate Therapeutics Inc.
- Shanghai JMT-Bio Inc.
Organization Involved with Phase 1 Indications (21)
- Eisai
- Eli Lilly
- Five Eleven Pharma, Inc.
- PharmaMar
- Huazhong University of Science and Technology
- University of Arizona
- Harvard University
- Guangzhou Medical University
- Italian Sarcoma Group
- University of Rochester
- Virginia Commonwealth University
- University of Utah
- Covance
- Opko
- Mario Negri Institute
- James B. and Lois R. Archer Charitable Foundation
- Gateway for Cancer Research
- Genor BioPharma Co., Ltd.
- IQVIA
- Peter MacCallum Cancer Centre
- KingMed Diagnostics
Organization Involved with Other Experimental Indications (1)